EU GMP Annex 1 Training: Sterile Manufacturing in Practice

Starts with a question: what does an EU inspector look for first at a sterile site? Not test results, but the design, people and strategy that keep contamination out. After a self-rating, two recent EU findings follow: the March 2026 HALMED inspection of two units of a sterile manufacturer in India, and a French statement of non-compliance for an aseptic biosimilar filler, with missing barriers, unrealistic airflow studies and weak simulations. You then meet JKL Pharma's sterile site in Singapore, where Line 2 fills a sterile-filtered liquid into vials in grade A under a RABS, plus a biologics filler in Dublin and a contract manufacturer in Frankfurt. The module outlines the fourteen modules, four practice exercises and final exam, and ends with a recap.

What you will be able to do

• Explain why Annex 1 puts design before monitoring and testing
• Recognise the failures behind two recent EU inspection findings
• Describe the aseptic filling line the course follows

Why it matters

Seeing what EU inspectors rated critical shows where your own sterile site must have design, discipline and data in place.

Practice: Practice: Why sterile manufacturing matters · 3 questions

Opens in 2022 with a contract manufacturer in Frankfurt whose head of production asks why lines that ran for fifteen years under the old Annex 1 must change. You then learn where Annex 1 sits in EU law, why it was revised, and that it was adopted in August 2022 and came into operation on 25 August 2023, with point 8.123 following in 2024. The module covers its scope, all sterile products from active substances to finished dosage forms, an ointment maker in Paris as a non-sterile contrast, and its limits as minimum requirements departed from only with justification. It explains the fixed order of risk control, design, then procedures, then monitoring, with terminal sterilisation preferred. You see JKL's gap review by section, including point 4.16 on alarms. It ends with a recap.

What you will be able to do

• Explain when the revised Annex 1 came into operation
• Describe the scope and organisation of Annex 1
• Apply the order of design, procedures and monitoring to a risk

Why it matters

Knowing the structure and principles of the revised Annex helps you plan which lines and procedures must change, and why.

Practice: Practice: Annex 1 at a glance · 3 questions

Returns to the 2026 inspection from Module 1, whose first critical finding was that the quality system did not cover sterile manufacturing, with inadequate deviation management and risk management not implemented. You then learn point 2.3 of the Annex in plain words: a contamination control strategy that defines critical control points across the facility and assesses every control and its monitoring together, from plant design onwards. The module answers whether a CCS means rewriting every procedure, gives one practical format built on the Annex points, and shows a contract manufacturer in Frankfurt using gamma-sterilised bags and an eye-drop maker in London using blow-fill-seal. It covers keeping the strategy alive through review and change, and the quality system's additions, including justified investigation scope. It ends with a recap and the first practice exercise, reviewing part of the strategy for Line 2.

What you will be able to do

• Explain what a contamination control strategy must include
• Build a CCS that links every control and its monitoring
• Describe what the quality system adds for sterile products

Why it matters

A living strategy shows an inspector on one page how every control works together, instead of a binder nobody reads.

Practice: Practice: The contamination control strategy · 3 questions

Starts with two 2026 inspections that found problems in the premises themselves, including smoke studies that did not match the activities seen on the line, rated critical, and inadequate material transfer. You then learn the four grades: grade A as the critical zone where product is open, with unidirectional airflow shown across all of it, and grade B as its background. The module explains how people and materials enter through airlocks of increasing cleanliness, with interlocked doors, approved lists and one-way routes, using a hospital injectables maker in Paris building a new suite. It covers air moving from cleaner to less clean at about ten pascals between grades, continuous recording, alarms, and smoke studies in real operation with retained videos, applied to JKL's Line 2. It ends with a recap.

What you will be able to do

• Explain the purpose of cleanroom grades A, B, C and D
• Check airlock design, interlocks and one-way routes
• Verify pressure cascades and smoke studies in real operation

Why it matters

Premises designed so clean air moves the right way are the first contamination control, before any test is run.

Practice: Practice: Premises, grades and airflow · 3 questions

Returns to the second unit of the Indian sterile site in 2026, where inadequate control of direct manual interventions in the critical zone was rated critical. You then learn the two barrier technologies, restricted access barrier systems and isolators, how they differ, and why the Annex says they should be considered for aseptic work, with any alternative justified in the strategy. The module covers background rooms: at least grade B for a RABS, and grade C for an open or grade D for a closed isolator, based on a written risk assessment, with a contract manufacturer in Frankfurt running an open isolator. It explains RABS door openings, frequent recorded glove checks, validated automated bio-decontamination with a sporicidal agent, and planning for failure, applied to JKL's Line 2. It ends with a recap.

What you will be able to do

• Explain how RABS and isolators differ and what background each needs
• Check glove integrity at each use and at set intervals
• Describe validated bio-decontamination of an isolator interior

Why it matters

A well-controlled barrier puts a wall between operators and product, removing the biggest source of contamination.

Practice: Practice: RABS and isolators · 3 questions

Opens with 2026 findings at a Chinese biosimilar maker on requalification of a syringe filling cleanroom and ineffective cleaning and disinfection, and a critical gap at the Indian site. You then learn qualification: classification against Table 1 particle limits and microbial limits from Table 2, at rest and in operation, including grade B values per cubic metre, settle plate and contact plate. The module explains requalification at least every six months for grades A and B and every twelve for C and D, with filter integrity, airflow and pressure checks, and a recovery period, as a hospital injectables maker in Paris re-set after a new machine. It covers a validated disinfection programme with more than one agent, a periodic sporicidal and sterile agents in A and B, with an eye-drop maker in London. It ends with the second practice exercise.

What you will be able to do

• Explain classification against the Table 1 particle limits
• Plan requalification intervals and tests for each grade
• Check that disinfection includes a periodic sporicidal agent

Why it matters

Proving rooms clean at set intervals, and disinfecting with validated agents, keeps them as clean as the day they were built.

Practice: Practice: Qualification and disinfection · 3 questions

Starts with the 2026 Indian inspection's critical finding of poorly designed equipment for dispensing, sampling and mixing, and major findings on cleaning validation. You then learn section 5: point 5.6 on qualifying, monitoring and maintaining sterilisers, air handling and water systems, point 5.7 on assessing unplanned maintenance for sterility impact, and sterilising direct and indirect contact parts. A supplier's single conveyor from the grade B filling room to capping shows why point 5.8 requires separate belts. The module covers section 6: utilities controlled by risk, gases filtered at the point of use, and water for injections, with point 6.7 on design, point 6.9 on turbulent flow against biofilm, daily sampling, and an eye-drop maker in London investigating an action limit excursion. It ends with a recap.

What you will be able to do

• Check equipment design, maintenance and return to use after repair
• Explain how water systems are designed and run against biofilm
• Investigate a water action limit excursion for product impact

Why it matters

Controlling everything that touches the product, from needles to water, closes routes contamination takes before anyone sees it.

Practice: Practice: Equipment and utilities · 3 questions

Returns to the 2026 Indian inspection, which rated non-compliant aseptic practices, training and behaviour critical in one unit and found gaps in garment sterility in another. You then learn who may enter grade A and B areas and how people are trained, assessed visually and microbially, included in a successful simulation and reassessed every year, so the busiest shift has been simulated first. The module explains gowning: a fresh sterile gown at each entry, enclosing all hair and facial skin, checked before, after and on exit. It covers aseptic behaviour, slow movement and clear first air, site phones for cleanroom use, a hospital supplier in Paris filling by hand, and visitors at a contract manufacturer in Frankfurt. It ends with Table 6 glove print limits and a recap.

What you will be able to do

• Explain how cleanroom staff are trained, qualified and reassessed
• Apply the gowning requirements for grade A and B entry
• Check personnel monitoring after interventions and on exit

Why it matters

Trained, well-gowned and watched people protect the product at the point where most contamination starts.

Practice: Practice: Personnel and gowning · 3 questions

Starts with the European Medicines Agency's 2025 annual report on suspected and confirmed quality defects in centrally authorised medicines. You then learn the first part of section 8: products are terminally sterilised wherever possible, because it gives greater sterility assurance, with a hospital supplier in Paris rethinking a stable saline filled aseptically for years. The module places each operation in its grade using Tables 3 and 4, with point 8.4 adding grade A with a grade C background where the strategy finds unusual risk. It covers aseptic work controlled through an authorised list of interventions evaluated by risk management and simulation, point 8.17 on recording every stoppage and intervention in the batch record, validated time limits, and a weekly observer at JKL. It ends with a recap.

What you will be able to do

• Explain why terminal sterilisation is preferred where possible
• Place each production step in its grade using Tables 3 and 4
• Record every intervention and stoppage in the batch record

Why it matters

Choosing the right route and controlling interventions removes risk by design and keeps the rest under control.

Practice: Practice: Production routes · 3 questions

Opens with a 2026 finding at a Chinese biosimilar maker on handling particles in two hundred litre single use bags with an extra filter. You then learn that every load pattern and cycle is validated, critical parameters controlled and recorded with a unique identifier, and cycle records reviewed for batch certification, including point 8.45 for stoppers. The module explains heat as the method of choice, radiation and ethylene oxide where heat cannot be used, why ultraviolet is not acceptable, and point 8.68 on depyrogenation, with an eye-drop maker in London sterilising plastic containers. It covers sterile filtration with validated filters, tested before use after sterilisation and after use, routine filtration records, and a contract manufacturer in Frankfurt where PUPSIT would lose product. It ends with the third practice exercise.

What you will be able to do

• Explain the sterilisation methods Annex 1 accepts and prefers
• Check that cycle records are reviewed for batch certification
• Set up sterile filtration with integrity tests before and after use

Why it matters

Sterility assurance comes from validated, recorded processes, because no test can check every unit.

Practice: Practice: Sterilisation and filtration · 3 questions

Starts with 2026 findings: no validated container closure integrity procedure for ampoules at the Indian site, rated critical, and visual inspection gaps at the Chinese biosimilar maker. You then learn that containers are closed by validated methods, small fused units such as ampoules are integrity tested one hundred percent, and other closures are tested on samples under a justified plan, since visual inspection is not an integrity test. The module explains inspecting every filled parenteral unit by qualified people or validated machines, recording results and trending defects. It covers the specific technologies in section 8: freeze drying, closed and single use systems, form-fill-seal with film controls, and blow-fill-seal, with an eye-drop maker in London. It ends with a recap.

What you will be able to do

• Explain when container closure integrity must be tested on every unit
• Check visual inspection by qualified people or validated machines
• Identify the specific risks of freeze drying and blow-fill-seal

Why it matters

Closing every container properly and checking every unit finds the one cracked or contaminated unit among thousands.

Practice: Practice: Closing, inspection, technologies · 3 questions

Returns to the French statement on the Chinese biosimilar maker, whose critical finding included observations on monitoring in grade A and B areas. You then learn that the monitoring programme is part of the strategy, designed by risk assessment and read as a whole. The module explains alert levels that catch deterioration early and action limits, at most the values in Tables 5 and 6, that trigger root cause, product impact including batches made before the result, and CAPA. It covers grade B microbial limits for air, settle plates, contact plates and gloves, continuous grade A monitoring and identifying isolates. You see a pattern on JKL Pharma's Line 2, a hospital supplier in Paris with excursions after maintenance, and a contract manufacturer in Frankfurt seeking faster results. It ends with a recap.

What you will be able to do

• Design a monitoring programme from the risk assessment
• Apply alert and action levels and assess product impact
• Trend monitoring results for patterns and changes in flora

Why it matters

Reading monitoring data as a pattern tells you quickly when controls are slipping, before contamination reaches product.

Practice: Practice: Environmental monitoring · 3 questions

Opens with the French authority's October 2026 statement, whose only critical finding began with deviations in the aseptic process simulation and weak assessment of their product impact. You then learn how a simulation imitates the routine process as closely as possible, with its interventions and worst cases, using point 9.36 for planning and air in place of the nitrogen overlay used for the product. The module covers growth promotion of filled units with reference organisms and local isolates, full documentation with reconciliation of units, and frequency: three consecutive successful runs at first, then about every six months per line and shift, with every operator once a year. It explains zero growth as the target, and investigation, quarantine and repeat runs after one contaminated unit, with a hospital supplier in Paris. It ends with the fourth practice exercise.

What you will be able to do

• Design a media fill that simulates the process at its worst
• Explain media fill frequency and operator qualification
• Respond to a failed aseptic process simulation

Why it matters

Simulating the real process at its worst shows whether aseptic filling works, without risking a real batch.

Practice: Practice: Aseptic process simulation · 3 questions

Starts with the scale of EU oversight in 2025: inspections requested by the European Medicines Agency's committees, statements of non-compliance, and GMP certificates recorded. You then learn section 10: bioburden tested on every batch, the sterility test as the last of many controls, samples from the start and end of the batch and after critical interventions, growth promotion of media, as a contract manufacturer in Frankfurt changed, and a procedure for out of trend data. An eye-drop maker in London treats each steriliser load as a sub-batch with its own sterility test, under point 10.6. You see JKL's review pack for certifying a Line 2 batch. The module ends with a road map, map one line, compare it with the Annex, rank gaps, fix them through change control and measure, plus the final exam.

What you will be able to do

• Explain what QC must test before a sterile batch is released
• Assemble the records needed to certify a sterile batch
• Apply the road map to compare one line with Annex 1

Why it matters

Certifying a batch on complete records, not one test, reflects that sterility is assured by the whole system.

Practice: Practice: QC, release, putting it together · 3 questions